Loading data
ACRVNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 59.99 m USD | 63.99 m USD | 46.02 m USD | 23.95 m USD | — |
| Operating profit | -84.11 m USD | -89.2 m USD | -67.1 m USD | -32.66 m USD | -16.18 m USD |
| Profit before tax | -77.83 m USD | -80.44 m USD | — | — | — |
| Income tax expense | 0 USD | — | — | — | — |
| Net income (reported basis) | -77.91 m USD | -80.6 m USD | -60.4 m USD | -31.17 m USD | -16.2 m USD |
| Basic earnings per share | -2.02 USD/share | -2.38 USD/share | -2.74 USD/share | -7.56 USD/share | -9.32 USD/share |
| Diluted earnings per share | -2.02 USD/share | -2.38 USD/share | -2.74 USD/share | -7.56 USD/share | -9.32 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.